ANI Pharmaceuticals, Inc.ANIPNASDAQ
LOADING
|||
Year-over-year earnings per share growth rate
| Period | Value |
|---|---|
| Q3 2025 | 221.62% |
| Q2 2025 | -47.14% |
| Q1 2025 | 227.27% |
| Q4 2024 | 56.69% |
| Q3 2024 | -807.14% |
| Q2 2024 | -116.67% |
| Q1 2024 | 2031.98% |
| Q4 2023 | -92.12% |
| Q3 2023 | 51.52% |
| Q2 2023 | 423.81% |
| Q1 2023 | 122.50% |
| Q4 2022 | 47.17% |
| Q3 2022 | 42.39% |
| Q2 2022 | 26.40% |
| Q1 2022 | 26.47% |
| Q4 2021 | -359.46% |
| Q3 2021 | 68.38% |
| Q2 2021 | -11800.00% |
| Q1 2021 | 103.33% |
| Q4 2020 | -850.00% |
| Q3 2020 | 103.88% |
| Q2 2020 | -74.58% |
| Q1 2020 | -43.90% |
| Q4 2019 | -228.13% |
| Q3 2019 | -41.82% |
| Q2 2019 | 1275.00% |
| Q1 2019 | -91.30% |
| Q4 2018 | 6.98% |
| Q3 2018 | 79.17% |
| Q2 2018 | 26.32% |
| Q1 2018 | 122.89% |
| Q4 2017 | -302.44% |
| Q3 2017 | 78.26% |
| Q2 2017 | 130.00% |
| Q1 2017 | 206.61% |
| Q4 2016 | -142.64% |
| Q3 2016 | 120.00% |
| Q2 2016 | -16.67% |
| Q1 2016 | -52.00% |
| Q4 2015 | -37.50% |